Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal

By Sugarbaker Paul  

Annals of Surgical Oncology, Vol. 17, Iss. 6, 2010-06 ,pp. : 1710-1712

Springer Publishing Company

Access to resources Recommend Favorite

Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin

By Blackham Aaron  

Annals of Surgical Oncology, Vol. 17, Iss. 10, 2010-10 ,pp. : 2720-2727

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma †

By Yan Tristan   Brun Erwin   Cerruto Carlos   Haveric Namik   Chang David   Sugarbaker Paul  

Annals of Surgical Oncology, Vol. 14, Iss. 1, 2007-01 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite

Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study

By Hommell-Fontaine J.   Isaac S.   Passot G.   Decullier E.   Traverse-Glehen A.   Cotte E.   You B.   Mohamed F.   Gilly F.   Glehen O.   Berger F.  

Annals of Surgical Oncology, Vol. 20, Iss. 12, 2013-11 ,pp. : 3892-3898

Springer Publishing Company

Access to resources Recommend Favorite

Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases

By Yan Tristan   Edwards Gary   Alderman Robert   Marquardt Christina   Sugarbaker Paul  

Annals of Surgical Oncology, Vol. 14, Iss. 2, 2007-02 ,pp. : 515-525

Springer Publishing Company

Access to resources Recommend Favorite